Drug Repurposing Strategy for the Treatment of COVID-19
HU Hong-Guo, LI Yan-Mei**
Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology Ministry of Education, Tsinghua University, Beijing 100084, China
World Health Orgazination.Coronavirus disease (COVID-2019) situation reports [EB/OL]. (2020-07-29)[2020-10-03]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
[2]
Wu Y, Ho W, Huang Y, et al. Lancet, 2020, 395(10228): 949-950
Yan R H, Zhang Y Y, Li Y N, et al. Science, 2020, 367(6485): 1444-1448
[5]
Li J J, Guo M Q, Tian X X, et al. Med., 2020, DOI: 10.1016/j.medj.2020.07.002
[6]
刘昌孝,王玉丽,闫凤英.中国抗生素杂志, 2020, 45(2): 93-102
[7]
Mohammad R D, Sara T G, Mohammad S D. Arch. Clin. Infect. Dis., 2017, 12(4): e13823
[8]
Veena N, Vannajan S L, Maturos M, et al. J. Theor. Biol., 2008, 254(4): 861-867
[9]
Andrew F G S. Pharmacol. Ther.,1993, 57(2/3): 203-235
[10]
高琪. 中国血吸虫病防治杂志, 2020, 32(2): 119-122
[11]
马振友.最新皮肤科药物手册.2版.西安:世界图书出版公司西安分公司, 2008: 153-154
[12]
Rameshwar U K, Ian A W. Proc. Natl. Acad. Sci. U. S. A., 2017, 114(2): 206-214
[13]
John H B, Kay M T, Lori E D, et al. N. Engl. J. Med., 2020, DOI: 10.1056/NEJMoa2007764
[14]
Gao Y, Yan L M, Huang Y C, et al. Science, 2020, 368(6492): 779-782
[15]
Gilead. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 [EB/OL].(2020-04-29)[2020-10-03]. https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
[16]
Wang Y M, Zhang D Y, Du G H, et al. Lancet, 2020, 395(10236): 1569-1578
[17]
U.S. Food and Drug Administration. Developing Products for Rare Diseases & Conditions [EB/OL].(2002-03-23)[2020-10-03]. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
[18]
Heidi L. Nature, 2020, 582(7813): 469-469
[19]
Kai K. Science, 2020, DOI: 10.1126/science.abd3683
